Hikma Pharmaceuticals Plc, Shire PLC And AstraZeneca plc All Look Attractive After Recent Declines

Have share price falls made Hikma Pharmaceuticals Plc (LON: HIK), Shire PLC (LON: SHP) and AstraZeneca plc (LON: AZN) strong buys?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The market’s recent declines have thrown up some great bargains for Foolish investors who aren’t afraid to invest against the grain. Three such bargains are Hikma Pharmaceuticals (LSE: HIK), Shire (LSE: SHP) and AstraZeneca (LSE: AZN).

These three highly defensive pharma stocks are now trading at their lowest valuations in more than two years, presenting a rare opportunity for long-term investors. 

Pipeline worries 

2016 is going to be a tough year for Astra. The company is set to lose patent protection on its blockbuster Crestor blood thinner this year, and at the beginning of February management warned that as a result of patent expirations, Astra’s sales and earnings would fall by a “low to mid-single-digit percentage” in 2016. Many City analysts believe that Astra’s sales declines will be at the lower end of the range mentioned above. 

Still, while Astra’s earnings are set to fall next year, management believes the company is still on track to increase revenues by three-quarters to $45bn by 2023. Astra’s management is pinning its hopes on the group’s best-in-class pipeline of opportunities, new drugs such as Brilinta, an anti-clotting drug, Durvalumab, and AZD9291. What’s more, to complement organic product development, Astra acquired several assets in a $10bn shopping spree last year to bolster its product pipeline and the group has had some success recently with the development of new oncology drugs. 

All in all, Astra’s near-term outlook might be worrying, but as new treatments come to market, the group should return to growth. Investors will get paid to wait for the company’s recovery as Astra currently supports a yield of 4.8%. The payout is covered one-and-a-half times by earnings per share, so it looks safe for now. 

Deal concerns 

Market jitters have pushed Shire’s shares to a 52-week low this week despite the fact that the company is now in a stronger position that it ever has been before. A string of deals has strengthened the company’s treatment pipeline, and pre-tax profit is expected to grow by 11% this year. Earnings per share are set to increase by 12% for 2016 and after recent declines, the company’s shares are trading at a forward P/E of only 16, a five-year low excluding one-off items. 

Shire’s shares currently support a dividend yield of 0.4%, which isn’t much, but the payout is covered more than 15 times by earnings per share, leaving plenty of room for payout growth. 

Buyout jitters 

Last year, Hikma agreed to pay $2.65bn in cash and shares for peer Roxane. However yesterday, Hikma said Roxane’s sales in 2015 were lower than the $680m it had estimated. As a result, Roxane’s price tag has been reduced, from $1.18bn to $647m. Hikma is buying Roxane for its pipeline, not the company’s products. In theory if everything goes to plan, over the long-term Hikma should benefit from the sudden reduction in price. 

Hikma’s earnings per share have expanded 130% since 2010 and City analysts have pencilled-in EPS growth of 16% for 2016. Based on this forecast the company is trading at a forward P/E of 23.2. Hikma’s shares only offer a token dividend yield of 0.7%, although the payout is covered five times by earnings per share. If the company can repeat its performance of the last five years, a valuation of 23.2 times earnings for Hikma’s shares seems appropriate. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

Just released: our top 3 small-cap stocks to consider buying in October [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

How I’d use an empty Stocks and Shares ISA to aim for a £1,000 monthly passive income

Here's how using a Stocks and Shares ISA really could help those of us who plan to invest for an…

Read more »

Investing Articles

This FTSE stock is up 20% and set for its best day ever! Time to buy?

This Fool takes a look at the half-year results from Burberry (LON:BRBY) to see if the struggling FTSE stock might…

Read more »

Investing Articles

This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

As the WH Smith share price falls 4% on annual results, is it still worth considering?

WH Smith took a hit after this morning’s results left shareholders unimpressed. With the share price down 4%, Mark Hartley…

Read more »

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »